Efficacy and safety of exercise rehabilitation in patients with hypertrophic cardiomyopathy

被引:12
|
作者
Wasserstrum, Yishay [1 ,2 ,3 ]
Barbarova, Iryna [2 ,3 ,4 ]
Lotan, Dor [1 ,2 ]
Kuperstein, Rafael [1 ,2 ]
Shechter, Michael [1 ,2 ]
Freimark, Dov [1 ,2 ]
Segal, Gad [2 ,3 ]
Klempfner, Robert [1 ,2 ]
Arad, Michael [1 ,2 ]
机构
[1] Chaim Sheba Med Ctr, Leviev Heart Inst, Ramat Gan, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[3] Chaim Sheba Med Ctr, Internal Med Dept T, Ramat Gan, Israel
[4] Meuhedet Hlth Serv HMO, Jerusalem, Israel
关键词
Heart failure; Hypertrophic cardiomyopathy; Exercise testing; Quality of life; Rehabilitation; VIGOROUS PHYSICAL-ACTIVITY; CHRONIC HEART-FAILURE; POPULATION; PREVALENCE; DIAGNOSIS; OUTCOMES; DISEASE;
D O I
10.1016/j.jjcc.2019.04.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: While physical rehabilitation has been shown to be beneficial and safe for patients suffering from heart failure, data on rehabilitation for hypertrophic cardiomyopathy (HCM) patients are limited. Methods: Forty-five HCM patients participated in an exercise rehabilitation program. Exercise capacity was measured in metabolic equivalent of task (METs) units and functional status was defined according to the New York Heart Association (NYHA). Self-reported measurements addressed the quality of life and daily life function. Results: Of the 45 participants, 32 completed at least 3 months of rehabilitation and had data from two sequential exercise tests. A significant increase in exercise capacity (from mean 5.3 to 6.7 METs, p = 0.01), was achieved at higher peak heart rates. Eighteen patients (56%) who showed improvement in exercise capacity did not differ in their NYHA class, clinical, electrocardiographic, or echo-Doppler parameters compared to those who did not improve. The benefit from training was associated with a lower exercise capacity at baseline and was most pronounced in those capable of less than 6.8 METs (p = 0.008). No significant arrhythmias or adverse events were recorded in HCM patients during participation. In 40% of participants, training improved the subjective perception of functional capacity and quality of life; only 4 patients (9%) discontinued their participation due to discomfort during or following training. The improvement in exercise capacity was comparable between HCM and a reference group of dilated cardiomyopathy patients. Conclusions: Exercise rehabilitation appears to be applicable and safe in HCM. It mainly benefits patients suffering from significant functional limitation. Larger prospective studies are needed to validate these findings and better characterize patients expected to benefit from these programs. (C) 2019 Japanese College of Cardiology Published by Elsevier Ltd.
引用
收藏
页码:466 / 472
页数:7
相关论文
共 50 条
  • [31] The efficacy and safety of coil embolization of septal branch in the treatment of patients with obstructive hypertrophic cardiomyopathy
    刘会
    China Medical Abstracts(Internal Medicine), 2018, 35 (01) : 24 - 25
  • [32] LONG-TERM EFFICACY AND SAFETY OF AFICAMTEN IN PATIENTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
    Saberi, Sara
    Abraham, Theodore P.
    Choudhury, Lubna
    Owens, Anjali Tiku
    Tower-Rader, Albree
    Rader, Florian
    Pavia, Pablo Garcia
    Olivotto, Iacopo
    Coats, Caroline
    Fifer, Michael A.
    Solomon, Scott D.
    Watkins, Hugh
    Heitner, Steve
    Jacoby, Dan
    Kupfer, Stuart
    Malik, Fady I.
    Meng, Lisa
    Wohltman, Amy
    Maron, Martin S.
    Masri, Ahmad
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 324 - 324
  • [33] Long-term efficacy and safety of ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy
    Gottlieb, A. Wang
    Edner, J.
    Gottlieb-Vedi, E.
    Yacoub, N.
    Shahim, A.
    Schwieler, J.
    Bastani, H.
    Drca, N.
    Saluveer, O.
    Jensen-Urstad, M.
    Braunschweig, F.
    Haugaa, K.
    Shahim, B.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [34] Long-Term Efficacy and Safety of Mavacamten in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy
    Day, Sharlene M.
    Udelson, James E.
    Bonow, Robert O.
    JAMA CARDIOLOGY, 2023, 8 (10) : 978 - 978
  • [35] Safety and efficacy of anti-tachycardia pacing in patients with hypertrophic cardiomyopathy implanted with an ICD
    Adduci, Carmen
    Semprini, Lorenzo
    Palano, Francesca
    Musumeci, Maria Beatrice
    Volpe, Massimo
    Autore, Camillo
    Francia, Pietro
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2019, 42 (06): : 610 - 616
  • [36] Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy
    Sherrid, MV
    Barac, I
    McKenna, WJ
    Elliott, PM
    Dickie, S
    Chojnowska, L
    Casey, S
    Maron, BJ
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (08) : 1251 - 1258
  • [37] Efficacy and safety of Mavacamten: A new era in the treatment of hypertrophic cardiomyopathy
    Sukaina, Mahnoor
    Waheed, Marium
    Ali, Naba
    Rasool, Raffat
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2022, 106 : 144 - 146
  • [38] Efficacy and Safety of Mavacamten in the Treatment of Hypertrophic Cardiomyopathy: A Systematic Review
    Bishev, Daniel
    Fabara, Stephanie
    Loseke, Isaac
    Alok, Akankcha
    Al-Ani, Hashim
    Bazikian, Yvette
    HEART LUNG AND CIRCULATION, 2023, 32 (09): : 1049 - 1056
  • [39] THE EFFICACY AND SAFETY OF EXERCISE PROGRAMS IN CARDIAC REHABILITATION
    HASKELL, WL
    MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 1994, 26 (07): : 815 - 823
  • [40] Exercise oxygen pulse kinetics in patients with hypertrophic cardiomyopathy
    Mapelli, Massimo
    Romani, Simona
    Magri, Damiano
    Merlo, Marco
    Cittar, Marco
    Mase, Marco
    Muratori, Manuela
    Gallo, Giovanna
    Sclafani, Matteo
    Carriere, Cosimo
    Zaffalon, Denise
    Salvioni, Elisabetta
    Mattavelli, Irene
    Vignati, Carlo
    De Martino, Fabiana
    Rovai, Sara
    Autore, Camillo
    Sinagra, Gianfranco
    Agostoni, Piergiuseppe
    HEART, 2022, 108 (20) : 1629 - +